Colesevelam
- Generic Name
- Colesevelam
- Brand Names
- Cholestagel, Lodalis, Welchol
- Drug Type
- Small Molecule
- CAS Number
- 182815-43-6
- Unique Ingredient Identifier
- 1XU104G55N
- Background
Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
- Indication
用于以胆固醇升高为主的高脂血症，当饮食和锻炼不能良好达到效果者，可单独使用或与他汀类合用。
- Associated Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH), Hyperlipidemias, Type 2 Diabetes Mellitus, Primary Hyperlipidemia
The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 38
- Registration Number
- NCT00951899
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1Hyperlipidemias
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 45
- Registration Number
- NCT00938405
- Locations
- 🇺🇸
Barbara Davis Center for Diabetes, Aurora, Colorado, United States
Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?
- Conditions
- Irritable Bowel SyndromeDiarrhea
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 24
- Registration Number
- NCT00911612
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Welchol as Monotherapy for Type 2 Diabetes Mellitus
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 357
- Registration Number
- NCT00789737
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 562
- Registration Number
- NCT00789750
Colesevelam Versus Placebo in Cholestatic Pruritus
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Foundation for Liver Research
- Target Recruit Count
- 38
- Registration Number
- NCT00756171
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
🇳🇱Amsterdam Medical Center, Amsterdam, Netherlands
🇳🇱University Medical Center Utrecht, Utrecht, Netherlands
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 65
- Registration Number
- NCT00754507
Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
- Conditions
- HypercholesterolemiaHyperlipidemia, Familial Combined
- Interventions
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 129
- Registration Number
- NCT00754039
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 72
- Registration Number
- NCT00753779
Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication
- Conditions
- Coronary Artery DiseaseCarotid Artery DiseasesAtherosclerosis
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 217
- Registration Number
- NCT00715273
- Locations
- 🇺🇸
University of Washington Coronary Atherosclerosis Research Lab, Seattle, Washington, United States
🇺🇸St. Luke's Idaho Cardiology, Boise, Idaho, United States
🇺🇸Yakima Heart Center, Yakima, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.